JPWO2020256096A1 - - Google Patents
Info
- Publication number
- JPWO2020256096A1 JPWO2020256096A1 JP2021526910A JP2021526910A JPWO2020256096A1 JP WO2020256096 A1 JPWO2020256096 A1 JP WO2020256096A1 JP 2021526910 A JP2021526910 A JP 2021526910A JP 2021526910 A JP2021526910 A JP 2021526910A JP WO2020256096 A1 JPWO2020256096 A1 JP WO2020256096A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019115496 | 2019-06-21 | ||
| JP2019115496 | 2019-06-21 | ||
| PCT/JP2020/024113 WO2020256096A1 (ja) | 2019-06-21 | 2020-06-19 | 悪性腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020256096A1 true JPWO2020256096A1 (https=) | 2020-12-24 |
| JPWO2020256096A5 JPWO2020256096A5 (https=) | 2022-03-16 |
| JP7574184B2 JP7574184B2 (ja) | 2024-10-28 |
Family
ID=74040503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526910A Active JP7574184B2 (ja) | 2019-06-21 | 2020-06-19 | 悪性腫瘍の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354858A1 (https=) |
| EP (1) | EP3988175A4 (https=) |
| JP (1) | JP7574184B2 (https=) |
| KR (1) | KR20220024821A (https=) |
| AU (1) | AU2020297166A1 (https=) |
| MA (1) | MA56549A (https=) |
| TW (1) | TWI856115B (https=) |
| WO (1) | WO2020256096A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| EP4284378A4 (en) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Ptentreating cancer in patient with pten inactivating mutation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012137870A1 (ja) * | 2011-04-06 | 2012-10-11 | 大鵬薬品工業株式会社 | 新規イミダゾオキサジン化合物又はその塩 |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2014203959A1 (ja) * | 2013-06-20 | 2014-12-24 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| WO2016136928A1 (ja) * | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| WO2017150725A1 (ja) * | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2657233T3 (da) | 2012-01-19 | 2014-09-22 | Taiho Pharmaceutical Co Ltd | 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP4093406A4 (en) * | 2020-01-24 | 2024-02-28 | Taiho Pharmaceutical Co., Ltd. | IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER |
| EP4284378A4 (en) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Ptentreating cancer in patient with pten inactivating mutation |
-
2020
- 2020-06-19 KR KR1020227002122A patent/KR20220024821A/ko not_active Withdrawn
- 2020-06-19 AU AU2020297166A patent/AU2020297166A1/en not_active Abandoned
- 2020-06-19 TW TW109120904A patent/TWI856115B/zh active
- 2020-06-19 EP EP20827927.3A patent/EP3988175A4/en active Pending
- 2020-06-19 WO PCT/JP2020/024113 patent/WO2020256096A1/ja not_active Ceased
- 2020-06-19 JP JP2021526910A patent/JP7574184B2/ja active Active
- 2020-06-19 US US17/620,419 patent/US20220354858A1/en active Pending
- 2020-06-19 MA MA056549A patent/MA56549A/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012137870A1 (ja) * | 2011-04-06 | 2012-10-11 | 大鵬薬品工業株式会社 | 新規イミダゾオキサジン化合物又はその塩 |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2014203959A1 (ja) * | 2013-06-20 | 2014-12-24 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| WO2016136928A1 (ja) * | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| WO2017150725A1 (ja) * | 2016-03-04 | 2017-09-08 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
Non-Patent Citations (1)
| Title |
|---|
| BROWN, JESSICA S. ET AL.: "Maximising the potential of AKT inhibitors as anti-cancer treatments", PHARMACOLOGY & THERAPEUTICS, vol. 172, JPN6020030022, 2017, pages 101 - 115, ISSN: 0005275434 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202114691A (zh) | 2021-04-16 |
| US20220354858A1 (en) | 2022-11-10 |
| WO2020256096A1 (ja) | 2020-12-24 |
| MA56549A (fr) | 2022-04-27 |
| TWI856115B (zh) | 2024-09-21 |
| AU2020297166A1 (en) | 2022-02-17 |
| EP3988175A4 (en) | 2023-06-28 |
| KR20220024821A (ko) | 2022-03-03 |
| JP7574184B2 (ja) | 2024-10-28 |
| EP3988175A1 (en) | 2022-04-27 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220106 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20211221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240502 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241008 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241016 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7574184 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |